DBD
Dược - Trang thiết bị Y tế Bình Định (Bidiphar) ·HOSE ·2026Q1
▼ Slightly negative
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, DBD is maintaining revenue, but margins are compressing slightly — profit is at an all-time high. What remains unclear is whether this is a short-term fluctuation or costs are starting to outpace revenue.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 448.1 | 510.0 | 439.7 | 474.5 | 441.0 | 477.9 | 432.8 | 433.1 | 383.8 | 444.5 | 411.4 | 414.1 |
| Growth | -12% | +16% | -7% | +8% | -8% | +10% | -0% | +13% | -14% | +8% | -1% | — |
| Net Income | 80.3 | 59.5 | 59.9 | 90.3 | 81.0 | 60.6 | 75.0 | 72.4 | 67.1 | 59.2 | 67.2 | 71.8 |
| Net Margin | 17.92% | 11.67% | 13.63% | 19.04% | 18.37% | 12.69% | 17.33% | 16.72% | 17.50% | 13.31% | 16.34% | 17.35% |
Drivers of DBD's profit
Net profit attributable to parent increased vs last year, mainly helped by lower selling expenses. Supporting and offsetting drivers:
Net profit attributable to parent declined vs prior quarter, mainly due to lower gross profit. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE fell from 17.9% to 16.3% — asset turnover weakened the most, though leverage still provided support.
Is the profit sustainable?
Margins narrowed but earnings quality remains clean — pressure is mainly operational.
What is driving the margin?
Net margin narrowed to 15.49%, falling 0.7pp. The main pressure is Gross margin fell 3.1pp, outweighing the improvement in SG&A / Revenue fell 2.0pp (with additional support from Net financial result / Revenue rose 0.8pp and Other profit / Revenue rose 0.2pp).
Margin is under pressure from multiple sides — temporary and structural components need to be separated to properly assess the risk.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Capital efficiency is declining — check whether the drag is from margins or turnover.
Is capital being deployed efficiently?
ROIC fell to 16.78%, losing 2.7pp. That translates to 16.78 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin narrowed 0.9pp and capital turnover fell 0.11x, while invested capital rose by 233bn — pressure came from both operational efficiency and asset efficiency.
Both margin and turnover weakened — this is a broad-based decline, and cyclical versus structural components need to be separated.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC declined — the balance sheet shows how capital is being deployed. Capital structure is conservative with low leverage — liabilities at 0.50x equity, net debt at 0.08x equity.
Inventory ended the period at 366.1bn, roughly 14.1% of total assets.
Over the last 12 months, working capital released 168.9bn of cash, mainly thanks to lower inventories and higher payables. Pressure from higher receivables only partly offset that benefit.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 41.0 days versus the same period last year. The main moves came from DIO fell 26.6 days, DSO fell 1.5 days, and DPO rose 12.8 days.
All 3 drivers (collection, inventory, payables) are improving — working capital turnover is strengthening across the board.
Watchpoints
CCC stands at 217.9 days, suggesting that working capital remains tied up for a relatively long operating cycle.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Financial risk is low — leverage is safe, both CFO and FCF are positive.
Leverage & Liquidity
Leverage looks fairly comfortable, with net debt / equity at 0.08x and interest coverage at 22.89x.
At present, short-term debt accounts for 19.0% of total debt, cash equals 45.2% of debt, and total debt stands at 269.0bn.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
With safe leverage noted above, cash flow below shows the self-funding capacity. Operating cash flow reached 615.2bn in 2025, against investing cash flow of -661.6bn.
Post-investment cash flow was negative +46.4bn. Financing cash flow was negative +65.0bn.
CFO / net income was 1.65x.
After spending +394.5bn on fixed-asset investment, the business generated trailing free cash flow of +82.9bn.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is heading the right way, but the current picture is still at partial confirmation — not yet a fully clean case. The positive points have clearly improved, showing the operating base is better than before. The brighter spot is earnings conversion is confirmed, with CFO/NI at 1.65x. The main risk still sits in working capital is tied up too long in the operating cycle, with CCC extended to 218 days.
Improvement: earnings conversion looks more confirmed, with CFO / net income at 1.65x.
Key risk: working capital remains tied up for too long, with cash cycle at 217.9 days.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
|
Net Revenue
|
1,865.4 | 1,727.5 | 1,651.8 | 1,554.8 | 1,558.5 |
|
Cost of Goods Sold
|
981.0 | 895.0 | 853.2 | 787.2 | 0.0 |
|
Gross Profit
|
884.4 | 832.6 | 798.5 | 767.7 | 622.6 |
|
Financial Expenses
|
14.6 | 16.9 | 17.9 | 12.0 | -8.6 |
|
Selling Expenses
|
418.3 | 404.2 | 375.6 | 357.4 | -276.4 |
|
General and Administrative Expenses
|
139.8 | 122.8 | 126.0 | 136.9 | -129.0 |
|
Operating Profit
|
349.1 | 329.1 | 322.0 | 298.7 | 230.9 |
|
Profit Before Tax
|
346.1 | 325.1 | 320.1 | 298.6 | 232.4 |
|
Net Income
|
291.9 | 275.2 | 269.1 | 243.6 | 184.1 |
|
Profit Attributable to Parent
|
291.9 | 275.2 | 269.1 | 243.6 | 184.1 |
|
Earnings per Share
|
2,674.00 | 2,530.00 | 3,092.00 | 2,799.00 | 3,195.99 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, MED, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.